Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Appoints Elizabeth Reed General Counsel
SAN DIEGO , Jan. 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Company's general legal, intellectual property, government
View HTML
Toggle Summary Retrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Dec. 29, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2017 at 10:30 a.m. PT .
View HTML
Toggle Summary Retrophin to Present at the BMO Capital Markets Healthcare Conference
SAN DIEGO , Nov. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference in New York City on Wednesday, December 14, 2016 at 10:30 a.m. ET .
View HTML
Toggle Summary Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Significant reduction of proteinuria compared to irbesartan Statistically significant difference in modified partial remission; complete remission also observed Further analysis supports sparsentan generally safe and well-tolerated SAN DIEGO , Nov. 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating RE-024 in PKAN
Phase 3 trial expected to initiate before year-end 2016
View HTML
Toggle Summary Retrophin Reports Third Quarter 2016 Financial Results
Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016 Third quarter revenues increased 21 percent year-over-year SAN DIEGO , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today reported its third quarter 2016 financial
View HTML
Toggle Summary Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
SAN DIEGO , Oct. 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session
View HTML
Toggle Summary Retrophin to Report Third Quarter 2016 Financial Results
SAN DIEGO , Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Dr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up
SAN DIEGO , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih , M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr.
View HTML
Toggle Summary Retrophin Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management.
View HTML